These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 39333697)

  • 1. Evaluating 4Kscore's role in predicting progression on active surveillance for prostate cancer independently of clinical information and PIRADS score.
    Hougen HY; Reis IM; Han S; Prakash NS; Thomas J; Stoyanova R; Castillo RP; Kryvenko ON; Ritch CR; Nahar B; Gonzalgo ML; Gaston SM; Abramowitz MC; Dal Pra A; Mahal BA; Pollack A; Parekh DJ; Punnen S
    Prostate Cancer Prostatic Dis; 2024 Sep; ():. PubMed ID: 39333697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimum threshold of the 4Kscore for biopsy in men with negative or indeterminate multiparametric magnetic resonance imaging.
    de Almeida S R; Thomas J; Mason MM; Becerra MF; Merhe A; Reis IM; Kwon D; Soodana-Prakash N; Tewari A; Patel V; Wagaskar V; Konety B; Kasraeian A; Czarniecki S; Thoreson GR; Kim EH; Swain S; Parekh DJ; Punnen S
    BJUI Compass; 2023 Sep; 4(5):591-596. PubMed ID: 37636212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing an effective strategy to improve the detection of significant prostate cancer by combining the 4Kscore and multiparametric MRI.
    Marzouk K; Ehdaie B; Vertosick E; Zappala S; Vickers A
    Urol Oncol; 2019 Oct; 37(10):672-677. PubMed ID: 31378585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Avoiding Unnecessary Magnetic Resonance Imaging (MRI) and Biopsies: Negative and Positive Predictive Value of MRI According to Prostate-specific Antigen Density, 4Kscore and Risk Calculators.
    Falagario UG; Martini A; Wajswol E; Treacy PJ; Ratnani P; Jambor I; Anastos H; Lewis S; Haines K; Cormio L; Carrieri G; Rastinehad AR; Wiklund P; Tewari A
    Eur Urol Oncol; 2020 Oct; 3(5):700-704. PubMed ID: 31548130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.
    Lin DW; Newcomb LF; Brown MD; Sjoberg DD; Dong Y; Brooks JD; Carroll PR; Cooperberg M; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Zheng Y;
    Eur Urol; 2017 Sep; 72(3):448-454. PubMed ID: 27889277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Utility of 4Kscore
    de la Calle CM; Fasulo V; Cowan JE; Lonergan PE; Maggi M; Gadzinski AJ; Yeung RA; Saita A; Cooperberg MR; Shinohara K; Carroll PR; Nguyen HG
    J Urol; 2021 Feb; 205(2):452-460. PubMed ID: 32897802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Four-year outcomes from a multiparametric magnetic resonance imaging (MRI)-based active surveillance programme: PSA dynamics and serial MRI scans allow omission of protocol biopsies.
    Gallagher KM; Christopher E; Cameron AJ; Little S; Innes A; Davis G; Keanie J; Bollina P; McNeill A
    BJU Int; 2019 Mar; 123(3):429-438. PubMed ID: 30113755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer-Data from the International Multicenter Prospective PRIAS Study.
    Luiting HB; Remmers S; Boevé ER; Valdagni R; Chiu PK; Semjonow A; Berge V; Tully KH; Rannikko AS; Staerman F; Roobol MJ
    Eur Urol Oncol; 2022 Dec; 5(6):651-658. PubMed ID: 35437217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adding a Coefficient for Race to the 4Kscore Improves Calibration for Black Men.
    Hougen HY; Sjoberg DD; Thomas J; Mahal BA; Vickers AJ; Punnen S
    J Urol; 2024 Mar; 211(3):392-399. PubMed ID: 38150383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the 4Kscore test as a predictor of reclassification in prostate cancer active surveillance.
    Borque-Fernando Á; Rubio-Briones J; Esteban LM; Dong Y; Calatrava A; Gómez-Ferrer Á; Gómez-Gómez E; Gil Fabra JM; Rodríguez-García N; López González PÁ; García-Rodríguez J; Rodrigo-Aliaga M; Herrera-Imbroda B; Soto-Villalba J; Martínez-Breijo S; Hernández-Cañas V; Soto-Poveda AM; Sánchez-Rodríguez C; Carrillo-George C; Hernández-Martínez YE; Okrongly D
    Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):84-90. PubMed ID: 30108375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of multiparametric magnetic resonance in active surveillance of a low-risk prostate cancer cohort from clinical practice.
    Chamorro Castillo L; García Morales L; Ruiz López D; Salguero Segura J; Valero Rosa J; Anglada Curado FJ; Mesa Quesada J; Blanca Pedregosa A; Carrasco Valiente J; Gómez Gómez E
    Prostate; 2023 Jun; 83(8):765-772. PubMed ID: 36895160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GÖTEBORG-2 Prostate Cancer Screening Trial.
    Josefsson A; Månsson M; Kohestani K; Spyratou V; Wallström J; Hellström M; Lilja H; Vickers A; Carlsson SV; Godtman R; Hugosson J
    Eur Urol; 2024 Sep; 86(3):223-229. PubMed ID: 38772787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Magnetic Resonance Imaging in Active Surveillance (MRIAS) Trial: Use of Baseline Multiparametric Magnetic Resonance Imaging and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate Biopsies.
    Amin A; Scheltema MJ; Shnier R; Blazevski A; Moses D; Cusick T; Siriwardena A; Yuen B; van Leeuwen PJ; Haynes AM; Matthews J; Brenner P; O'Neill G; Yuen C; Delprado W; Stricker P; Thompson J
    J Urol; 2020 May; 203(5):910-917. PubMed ID: 31825297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer.
    Parekh DJ; Punnen S; Sjoberg DD; Asroff SW; Bailen JL; Cochran JS; Concepcion R; David RD; Deck KB; Dumbadze I; Gambla M; Grable MS; Henderson RJ; Karsh L; Krisch EB; Langford TD; Lin DW; McGee SM; Munoz JJ; Pieczonka CM; Rieger-Christ K; Saltzstein DR; Scott JW; Shore ND; Sieber PR; Waldmann TM; Wolk FN; Zappala SM
    Eur Urol; 2015 Sep; 68(3):464-70. PubMed ID: 25454615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic Resonance Imaging-guided Active Surveillance Without Annual Rebiopsy in Patients with Grade Group 1 or 2 Prostate Cancer: The Prospective PROMM-AS Study.
    Valentin B; Arsov C; Ullrich T; Al-Monajjed R; Boschheidgen M; Hadaschik BA; Giganti F; Giessing M; Lopez-Cotarelo C; Esposito I; Antoch G; Albers P; Radtke JP; Schimmöller L
    Eur Urol Open Sci; 2024 Jan; 59():30-38. PubMed ID: 38298772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Finding the Wolf in Sheep's Clothing: The 4Kscore Is a Novel Blood Test That Can Accurately Identify the Risk of Aggressive Prostate Cancer.
    Punnen S; Pavan N; Parekh DJ
    Rev Urol; 2015; 17(1):3-13. PubMed ID: 26028995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing patient's selection for prostate biopsy: A single institution experience with multi-parametric MRI and the 4Kscore test for the detection of aggressive prostate cancer.
    Punnen S; Nahar B; Soodana-Prakash N; Koru-Sengul T; Stoyanova R; Pollack A; Kava B; Gonzalgo ML; Ritch CR; Parekh DJ
    PLoS One; 2018; 13(8):e0201384. PubMed ID: 30092002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance.
    Walton Diaz A; Shakir NA; George AK; Rais-Bahrami S; Turkbey B; Rothwax JT; Stamatakis L; Hong CW; Siddiqui MM; Okoro C; Raskolnikov D; Su D; Shih J; Han H; Parnes HL; Merino MJ; Simon RM; Wood BJ; Choyke PL; Pinto PA
    Urol Oncol; 2015 May; 33(5):202.e1-202.e7. PubMed ID: 25754621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 4Kscore Predicts the Grade and Stage of Prostate Cancer in the Radical Prostatectomy Specimen: Results from a Multi-institutional Prospective Trial.
    Punnen S; Nahar B; Prakash NS; Sjoberg DD; Zappala SM; Parekh DJ
    Eur Urol Focus; 2017 Feb; 3(1):94-99. PubMed ID: 28720374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular and diffusion features for identification of clinically significant prostate cancer in PI-RADS 3 lesions.
    Ajami T; Han S; Porto JG; Kimbel I; Szczotka Z; Guerard T; VanderVeer-Harris N; Ledesma BR; Acosta PC; Kryvenko ON; Parekh DJ; Stoyanova R; Reis IM; Punnen S
    Urol Oncol; 2024 Nov; 42(11):370.e9-370.e14. PubMed ID: 38971674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.